BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 24629496)

  • 21. Biological monitoring of human exposure to coal tar. Urinary mutagenicity assays and analytical determination of polycyclic aromatic hydrocarbon metabolites in urine.
    Clonfero E; Jongeneelen F; Zordan M; Levis AG
    IARC Sci Publ; 1990; (104):215-22. PubMed ID: 2228119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of metabolic genotype GSTM1 on levels of urinary mutagens in patients treated topically with coal tar.
    Gabbani G; Pavanello S; Nardini B; Tognato O; Bordin A; Fornasa CV; Bezze G; Clonfero E
    Mutat Res; 1999 Mar; 440(1):27-33. PubMed ID: 10095126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer risk from incidental ingestion exposures to PAHs associated with coal-tar-sealed pavement.
    Williams ES; Mahler BJ; Van Metre PC
    Environ Sci Technol; 2013 Jan; 47(2):1101-9. PubMed ID: 23181746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Formation of DNA adducts in the skin of psoriasis patients, in human skin in organ culture, and in mouse skin and lung following topical application of coal-tar and juniper tar.
    Schoket B; Horkay I; Kósa A; Páldeák L; Hewer A; Grover PL; Phillips DH
    J Invest Dermatol; 1990 Feb; 94(2):241-6. PubMed ID: 2299199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human skin aryl hydrocarbon hydroxylase. Induction by coal tar.
    Bickers DR; Kappas A
    J Clin Invest; 1978 Nov; 62(5):1061-8. PubMed ID: 711851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uptake of pyrene in a breast-fed child of a mother treated with coal tar.
    Scheepers PT; van Houtum JL; Anzion RB; Harder R; Bos RP; van der Valk PG
    Pediatr Dermatol; 2009; 26(2):184-7. PubMed ID: 19419468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of risk of developing bladder cancer among workers exposed to coal tar pitch volatiles in the primary aluminum industry.
    Tremblay C; Armstrong B; Thériault G; Brodeur J
    Am J Ind Med; 1995 Mar; 27(3):335-48. PubMed ID: 7747740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary mutagenicity and genotoxic risk in children with psoriasis after therapeutic exposure to polycyclic aromatic hydrocarbons and ultraviolet radiation.
    Borska L; Smejkalova J; Cerna M; Hamakova K; Kucera I; Kremlacek J; Pelikanova D; Fiala Z
    Mutat Res; 2010 Feb; 696(2):144-7. PubMed ID: 20096371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mutagenic effects of coal tar used in the treatment of psoriasis].
    Gardosová D; Mezencevová V; Kalina I; Hejj F; Kopka M; Petrovicová J
    Bratisl Lek Listy; 1997 Mar; 98(3):146-9. PubMed ID: 9264819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotoxic effect of Goeckerman regimen of psoriasis.
    Fiala Z; Borska L; Pastorkova A; Kremlacek J; Cerna M; Smejkalova J; Hamakova K
    Arch Dermatol Res; 2006 Oct; 298(5):243-51. PubMed ID: 16902768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mutagenic activity of urine of patients with psoriasis treated with pharmaceutical black coal tar].
    Gardosová D; Kalina I; Hejj F; Mezencevová V; Salagovic J; Némethová G
    Cas Lek Cesk; 1994 Aug; 133(15):463-6. PubMed ID: 8082111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comment on "cancer risk from incidental ingestion exposures to PAHs associated with coal-tar-sealed pavement".
    Magee B; Keating-Connolly J
    Environ Sci Technol; 2014; 48(1):868-9. PubMed ID: 24328310
    [No Abstract]   [Full Text] [Related]  

  • 33. A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand.
    Thawornchaisit P; Harncharoen K
    J Med Assoc Thai; 2007 Oct; 90(10):1997-2002. PubMed ID: 18041415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to comment on "cancer risk from incidental ingestion exposures to PAHs associated with coal-tar-sealed pavement".
    Williams ES; Mahler BJ; Van Metre PC
    Environ Sci Technol; 2014; 48(1):870-1. PubMed ID: 24328334
    [No Abstract]   [Full Text] [Related]  

  • 35. [Longitudinal study of the excretion of 1-hydroxypyrene in urine after external treatment with coal tar].
    Nenoff P; Richter B; Will W; Haustein UF
    Hautarzt; 1997 Apr; 48(4):240-5. PubMed ID: 9206711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Holistic development of coal tar lotion by embedding design of experiments (DoE) technique: preclinical investigations.
    Sharma M; Sharma G; Singh B; Dhiman V; Bhadada SK; Katare OP
    Expert Opin Drug Deliv; 2020 Feb; 17(2):255-273. PubMed ID: 31990219
    [No Abstract]   [Full Text] [Related]  

  • 37. Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: a quantitative review to 2005.
    Bosetti C; Boffetta P; La Vecchia C
    Ann Oncol; 2007 Mar; 18(3):431-46. PubMed ID: 16936186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double blind, randomized, controlled clinical trial to assess the efficacy of a new coal tar preparation (Exorex) in the treatment of chronic, plaque type psoriasis.
    Smith CH; Jackson K; Chinn S; Angus K; Barker JN
    Clin Exp Dermatol; 2000 Nov; 25(8):580-3. PubMed ID: 11167965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effects of calcipotriol ointment (50 micrograms/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis.
    Pinheiro N
    Br J Clin Pract; 1997; 51(1):16-9. PubMed ID: 9158266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Coal tar dissolved in chloroform in dermatological therapy. Clinical trials].
    Tobia L
    Minerva Med; 1971 Mar; 62(22):1188-9. PubMed ID: 5551951
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.